Related Experiment Videos
Platelet-derived growth factor is decreased in patients with myeloproliferative disorders
O Katoh1, A Kimura, A Kuramoto
1Department of Internal Medicine, Research Institute for Nuclear Medicine and Biology, Hiroshima University, Japan.
Abstract:
Platelet-derived growth factor (PDGF) has been suggested to play some role in the pathogenesis of myelofibrosis frequently encountered in patients with myeloproliferative disorders (MPD). In this study we measured PDGF activity and PF4 content in circulating platelets of patients with MPD. Both factors were lower than those of normal controls. PDGF activity in patients with myelofibrosis was slightly lower than in those without fibrosis. However, when adjusted to whole blood volume, there was a positive correlation between platelet count and PDGF activity per ml whole blood. Nevertheless, no correlation was found between activity and grade of bone marrow fibrosis. These results may support the idea that an abnormal release of PDGF occurs from platelets or megakaryocytes in the bone marrow environment, resulting in the stimulation of fibroblast proliferation, and hence, the occurrence of myelofibrosis in patients with MPD.
Insights
Platelet-derived growth factor (PDGF) levels were lower in myeloproliferative disorder (MPD) patients. Abnormal PDGF release from platelets may contribute to myelofibrosis in MPD.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Myelofibrosis is a serious complication of myeloproliferative disorders (MPD).
- Platelet-derived growth factor (PDGF) is implicated in the pathogenesis of myelofibrosis.
- The precise role of PDGF in MPD-associated myelofibrosis requires further elucidation.
Purpose of the Study:
- To measure PDGF activity and PF4 content in circulating platelets of MPD patients.
- To investigate the correlation between PDGF levels, platelet counts, and the grade of bone marrow fibrosis in MPD.
- To explore the potential role of abnormal PDGF release in myelofibrosis development.
Main Methods:
- Quantification of PDGF activity and PF4 content in circulating platelets from MPD patients and healthy controls.
- Comparison of PDGF levels between MPD patients with and without myelofibrosis.
- Statistical analysis to assess correlations between platelet count, PDGF activity, and bone marrow fibrosis grade.
Main Results:
- PDGF activity and PF4 content were lower in MPD patients compared to normal controls.
- PDGF activity in patients with myelofibrosis was slightly lower than in those without fibrosis.
- A positive correlation was observed between platelet count and PDGF activity per ml of whole blood, but not with the grade of bone marrow fibrosis.
Conclusions:
- Circulating PDGF levels are reduced in MPD patients.
- Results suggest abnormal PDGF release from platelets or megakaryocytes within the bone marrow microenvironment.
- This abnormal release may stimulate fibroblast proliferation, contributing to myelofibrosis in MPD.